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Abstract
Background: A recent ovarian cancer genome-wide association study (GWAS) identified a locus on 9p22 associated with
reduced ovarian cancer risk. The single nucleotide polymorphism (SNP) markers localize to the BNC2 gene, which has been
associated with ovarian development.
Methods: We analyzed the association of 9p22 SNPs with transvaginal ultrasound (TVU) screening results and CA-125 blood
levels from participants without ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO);
1,106 women with adequate ultrasound screening results and available genotyping information were included in the study.
Results: We observed a significantly increased risk of abnormal suspicious TVU results for seven SNPs on 9p22, with odds
ratios between 1.68 (95% CI: 1.04–2.72) for rs4961501 and 2.10 (95% CI: 1.31–3.38) for rs12379183. Associations were
restricted to abnormal suspicious findings at the first TVU screen. We did not observe an association between 9p22 SNPs
and CA-125 levels.
Conclusions: Our findings suggest that 9p22 SNPs, which were found to be associated with decreased risk of ovarian cancer
in a recent GWAS, are associated with sonographically detectable ovarian abnormalities. Our results corroborate the
relevance of the 9p22 locus for ovarian biology. Further studies are required to understand the complex relationship
between screening abnormalities and ovarian carcinogenesis and to evaluate whether this locus can influence the risk
stratification of ovarian cancer screening.
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Introduction
Ovarian cancer is the 8
th most common cancer and the 5
th
leading cause of cancer death among women in the US [1].
Currently available early detection strategies are based on serum
CA-125 measurement and transvaginal ultrasound (TVU) [2,3].
However, these tests have not been shown to improve mortality
from ovarian cancer; most women present at advanced disease
stages [4].
The use of TVU is hampered by false-positive findings, resulting
in unnecessary surgical procedures with possible complications
[5,6]. At the initial screening round in the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial (PLCO), 1338 of
28,816 women (4.6%) were found to have abnormal TVU results,
but only 13 invasive cancers were detected, translating to a positive
predictive value of only 1% [2]. A recent evaluation of false
positive TVU test results in PLCO showed that a wide variety of
benign changes -not associated with ovarian cancer risk- are
responsible for abnormal ultrasound findings [7]. A better
understanding of ovarian cancer etiology is required to develop
improved early detection and prevention strategies. Similarly, new
approaches are needed to identify the subset of high risk women
who might benefit from current screening modalities.
A recent genome wide association study identified the first
ovarian cancer susceptibility locus with genome-wide significance
[8]. A locus on 9p22 was associated with reduced ovarian cancer
risk; the most significant SNP is rs3814113 (odds ratio=0.82;
ptrend 5.1610
219). The locus includes the basonuclein 2 (BNC2) gene;
eight SNPs were located within intron 2 of the gene. BNC2 is
highly expressed in reproductive tissues and specifically implicated
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21731Table 1. Risk factors and screening results in the subgroup with SNP data.
Variable
Baseline
Abnormal TVU
Incident
Abnormal TVU Other TVU
Baseline vs.
Incident/Other
x
2 p-value
Baseline/Incident vs.
Other
x
2 p-value
Age at entry
55–59 12 (24.0) 7 (15.2) 246 (24.4)
60–64 15 (30.0) 13 (28.3) 321 (31.8)
65–69 14 (28.0) 14 (30.4) 280 (27.7)
70+ 9 (18.0) 12 (26.1) 163 (16.1) 0.99 0.43
Total 50 46 1010
Race
Caucasian 43 (86.0) 37 (80.4) 912 (90.3)
Non-Caucasian 7 (14.0) 9 (19.6) 98 (9.7) 0.38 0.03
Total 50 46 1010
Nulliparous
No 45 (90.0) 42 (91.3) 912 (90.4)
Yes 5 (10.0) 4 (8.7) 97 (9.6) 0.92 0.94
Total 50 46 1009
Family hx breast cancer
No 44 (88.0) 36 (78.3) 850 (84.6)
Yes, female relative 6 (12.0) 8 (17.4) 138 (13.7)
Yes, male relative 0 1 (2.2) 2 (0.2)
Possibly 0 1 (2.2) 15 (1.5) 0.78 0.48
Total 50 46 1005
Family hx ovarian cancer
No 47 (94.0) 41 (89.1) 949 (94.4)
Yes, immediate family 3 (6.0) 3 (6.5) 40 (4.0)
Possibly 0 2 (4.4) 16 (1.6) 0.53 0.53
Total 50 46 1005
PMH use
Ever 33 (66.0) 30 (65.2) 617 (61.1)
Never 17 (34.0) 16 (34.8) 388 (38.5)
Unknown 0 0 4 (0.4) 0.74 0.59
Total 50 46 1009
OC use
Never 23 (46.0) 26 (56.5) 511 (50.7)
Ever 27 (54.0) 20 (43.5) 496 (49.3) 0.49 0.96
Total 50 46 1007
Smoker
Never 13 (26.0) 13 (28.3) 324 (32.1)
Current 15 (30.0) 16 (34.8) 310 (30.7)
Former 22 (44.0) 17 (37.0) 376 (37.2) 0.57 0.6
Total 50 46 1010
Benign cyst or tumor
No 35 (79.5) 37 (84.1) 867 (90.4)
Yes 9 (20.5) 7 (15.9) 92 (9.6) 0.02 0.01
Total 44 44 959
Age of first menstrual period
,10 0 0 12 (1.2)
10–11 8 (16.0) 12 (26.1) 167 (16.6)
12–13 27 (54.0) 27 (58.7) 572 (56.8)
14–15 12 (24.0) 5 (10.9) 215 (21.4)
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of 9p22 SNPs with abnormal ovarian screening results among
women in PLCO without ovarian cancer.
Materials and Methods
We included all 1,106 women with TVU data and genome-
wide scan data covering the 9p22 region from the PLCO
screening arm (total n=39,115 of whom n=34,261 had not had
prior oophorectomy). Each of the 10 screening centers obtained
local Institutional Review Board approval to carry out the trial.
NCI Institutional Review Board Approval was obtained to
conduct genotyping among women who agreed to participate in
genetic studies. We included only women with adequate TVU
results and genotyping information for at least one of the SNPs on
9p22 previously found to be associated with ovarian cancer [8]. In
total, 568 controls and 538 cases from genome wide association
studies of pancreatic, lung, bladder, breast, renal, colon cancer,
and glioma were included [11,12]. Table 1 shows the distribution
of cancer cases by site with the respective TVU results. Of note,
most cancers developed during the follow-up of PLCO and were
not present at the baseline TVU screen. TVU was performed at
baseline and annually for four years according to the PLCO
protocol at the screening centers [13]. TVU results were
categorized as normal; abnormal not suspicious for ovarian
cancer; and abnormal, suspicious for ovarian cancer as previously
described [2]. Women with suspicious findings were referred for
follow-up [14]. Ovaries were measured along the major and minor
axes in both transverse and longitudinal planes, and the prolate
ellipsoid formula (width6height6thickness60.523) was used to
calculate the volume of each ovary and/or cyst. In brief, the
following findings were considered abnormal suspicious, i.e.
screening positive: ovarian volume .10 cm
3; cyst volume
.10 cm
3; any solid area or papillary projection extending into
the cavity of a cystic ovarian tumor of any size; or any mixed
(solid/cystic) component within a cystic ovarian tumor. CA-125
was measured using the Centocor CA-125II radioimmunoassay on
serum prepared and frozen within 2 hours of blood draw [2].
Genotypingwas performed at the National CancerInstitute Core
Genotyping Facility and Fred Hutchinson Cancer Research Center
on the HumanHap550 Infinium II and Human 610-Quad chips
(Illumina, San Diego, CA). Genotyping quality control followed
standard procedures at the Core Genotyping Facility [11,12]: DNA
samples were selected for genotyping based on pre-genotyping
quality control measures performed for the GWAS at the Core
Genotyping Facility. Samples with less than 98% completion rate
wereexcluded from the analysis and SNP assays with locus call rates
lowerthan 90%were excluded.SNPs with extreme departures from
Hardy-Weinberg proportions (P,1610
27) were excluded from the
primary analyses due to their increased likelihood of spurious
associations due to problematic assays or genotyping calling. Ten
9p22 SNPs identified in the ovarian GWAS passed these quality
control metrics and were included in the analysis: rs10756819,
rs10810666, rs10962656, rs12379183, rs12379687, rs1339552,
rs2153271, rs3814113, rs4961501, rs7861573.
TVU results were dichotomized into abnormal suspicious vs.
normal and abnormal not suspicious. SNP associations were
studied in relation to three outcomes: The TVU result at the first
screen performed, the most severe TVU result of all screens, and
the most severe incident TVU result (i.e. after excluding exams
with abnormal screening results at the first screen). We used
additive models defining the minor allele as risk allele to study the
association of 9p22 SNPs with abnormal suspicious TVU results
restricted to Caucasian individuals. We ran crude models and
models adjusted for age as a continuous variable. For sensitivity
analyses, we re-ran the models excluding individuals who were
genotyped at the Fred Hutchinson Cancer Center but did not see
any effect related to the site of genotyping. A sensitivity analysis
restricted to control women only did not change the direction of
the results. We used the Bonferroni correction as a conservative
adjustment for multiple comparisons (n=10), lowering the
significance threshold to 0.005. Next, we studied the risk of
abnormal TVU results associated with combinations of 0–2, 3–5,
and 6–8 minor alleles from the four most significantly associated
SNPs (rs10756819, rs12379183, rs3814113, and rs7861573). In
addition, we combined the two least correlated SNPs (rs7861573
and rs10810666, Figure 1) and studied the association with
abnormal TVU results creating three categories: Homozygous
major alleles at both SNPs, one SNP with homozygous major
alleles, and no SNP with homozygous major alleles. In all women,
we analyzed the relationship between 9p22 SNPs and ovarian
volume in 5-year age groups and by individual genotypes for
Variable
Baseline
Abnormal TVU
Incident
Abnormal TVU Other TVU
Baseline vs.
Incident/Other
x
2 p-value
Baseline/Incident vs.
Other
x
2 p-value
16+ 3 (6.0) 2 (4.4) 41 (4.1) 0.86 0.57
Total 50 46 1007
GWAS case/control
Control 22 (44.0) 26 (56.5) 520 (51.5)
Case 28 (56.0) 20 (43.5) 490 (48.5) 0.29 0.78
Bladder 4 6 84
Breast 4 1 32
Colon 4 1 79
Lung 14 9 249
Pancreas 2 3 46
Total 50 46 1010
TVU=transvaginal ultrasound; Family hx=family history; PMH=Post-menopausal hormone; OC=oral contraceptive; GWAS=genome-wide association study.
doi:10.1371/journal.pone.0021731.t001
Table 1. Cont.
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with abnormal TVU results and genotyping data available, we
explored the relationship between specific TVU characteristics
including number of cysts, cyst diameter, and cyst volume with
genotypes (dichotomized as AA vs. AB/BB) of rs10756819,
rs12379183, and rs3814113.. In addition, we explored the
association of 9p22 SNPs with CA-125 levels at baseline and with
highest CA-125 levels measured at all screening visits stratifying by
5-year age groups over the complete age range of women included
in this analysis (age at entry: 55–74 years). Haploview (http://
www.broad.mit.edu/mpg/haploview/) was used to assess pair-
wise linkage disequilibrium (LD) patterns among all women
included in the analysis [15]. All statistical analyses were
performed using SAS (SAS 9.1, SAS Institute, Cary, NC, USA).
Figure 1. LD-plot of 10 SNPs on 9p22 from individuals included in the analysis. The LD-plot was generated with Haploview based on r
2 of
the 10 SNPs on 9p22 in 992 Caucasian women with genotyping information and transvaginal ultrasound results available.
doi:10.1371/journal.pone.0021731.g001
Table 2. Association of 10 SNPs on 9p22 with abnormal TVU screening results.
Worst TVU result (n=992) First TVU result (n=992) Incident TVU result (n=949)
SNP Case/Control OR
Lower
CL
Upper
CL P-value Case/Control OR
Lower
CL
Upper
CL P-value Case/Control OR
Lower
CL
Upper
CL P-value
rs10756819 80/912 1.48 1.05 2.08 0.0254 43/949 2.01 1.28 3.14 0.0024* 37/912 1.01 0.61 1.68 0.9763
rs 10810666 80/910 1.27 0.86 1.89 0.2275 43/947 1.72 1.05 2.82 0.0307 37/910 0.84 0.45 1.59 0.5982
rs 10962656 80/911 1.22 0.79 1.89 0.3684 43/948 1.73 1.02 2.94 0.0423 37/911 0.73 0.34 1.54 0.4024
rs 12379183 79/909 1.46 1.01 2.13 0.0464 42/946 2.10 1.31 3.38 0.0022* 37/909 0.90 0.50 1.64 0.7363
rs 12379687 79/911 1.21 0.78 1.87 0.3884 43/947 1.68 0.99 2.85 0.0527 36/911 0.74 0.35 1.55 0.4184
rs 1339552 75/790 1.10 0.78 1.56 0.5870 41/824 1.30 0.82 2.05 0.2602 34/790 0.90 0.54 1.50 0.6934
rs 2153271 78/911 1.12 0.80 1.58 0.5030 42/947 1.42 0.91 2.23 0.1241 36/911 0.85 0.51 1.41 0.5263
rs 3814113 79/912 1.39 0.98 1.97 0.0652 42/949 1.93 1.22 3.06 0.0049* 37/912 0.93 0.55 1.57 0.7849
rs 4961501 80/910 1.25 0.85 1.82 0.2563 43/947 1.68 1.04 2.72 0.0352 37/910 0.84 0.47 1.52 0.5711
rs 7861573 79/908 1.42 0.97 2.07 0.0694 42/945 1.99 1.23 3.21 0.0048* 37/908 0.90 0.50 1.64 0.7414
Per allele odds ratios obtained with an additive model restricted to the Caucasian population for the association of 9p22 SNPs with abnormal screening results are
shown. Cases are women with suspicious screening results; controls are women with normal or non-suspicious screening results. Worst TVU results indicate abnormal
TVU results at any screen during the 4-year follow-up. First TVU results indicate abnormal TVU results at the first screen a woman participated in. Incident TVU results are
abnormal results among women that were normal or non-suspicious at the first screening. An asterisk indicates p-values lower than 0.005, the significance level after
conservative Bonferroni correction.
doi:10.1371/journal.pone.0021731.t002
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Overall, 96 of the 1106 women included in this analysis had
abnormal TVU screening results (8.7%) at any screening visit. In
50 women, abnormal TVU results were found at the first
screening visit in PLCO (baseline abnormal TVU result), in the
remaining 46 women, the abnormal TVU result was reported
after an initially normal finding (incident abnormal TVU result).
Table 1 shows demographic and risk factor features of women
included in this analysis, grouped in three categories: Abnormal
TVU result at baseline, incident abnormal TVU results, and
normal TVU results. Except for race and a previous history of
Table 3. Association of SNP combinations with abnormal TVU results.
SNP combination Case/Control OR Lower CL Upper CL P-value
rs10756819/rs12379183/rs3814113/rs7861573 43/949 1.951 1.259 3.022 0.0028
rs7861573/rs10810666 43/949 1.616 1.141 2.290 0.0069
Per allele odds ratios obtained with an additive model restricted to the Caucasian population for the association of combinations of 9p22 SNPs with abnormal screening
results are shown. First, combinations of the four most strongly associated SNPs were analyzed. Three groups were created based on the number of minor alleles: 0–2
alleles present, 3–5 alleles present, 6–8 alleles present. Next, the two least correlated SNPs were combined. For the two-SNP combination, homozygote major alleles
were considered low risk, while heterozygous alleles and homozygous minor allele genotypes were considered high risk. Three groups were created as follows: low risk
by both SNPs, high risk by either one of the SNPs, and high risk by both SNPs.
doi:10.1371/journal.pone.0021731.t003
Table 4. 9p22 genotypes and ovarian volume.
SNP Genotype Age N First volume median cm
3 (IQR) Maximal volume median cm
3 (IQR)
rs12379183 AA All 518 1.2 (1.6) 1.6 (2.0)
55–59 122 1.2 (1.6) 1.6 (2.3)
60–64 169 1.2 (1.8) 1.6 (2.3)
65–69 141 1.2 (1.3) 1.6 (1.6)
70–74 86 1.1 (1.6) 1.65 (2.4)
AG All 291 1.3 (1.6) 1.8 (2.1)
55–59 71 1.5 (1.7) 1.8 (1.4)
60–64 93 1.4 (2.2) 2.1 (2.7)
65–69 77 1.4 (1.6 1.6 (2.1)
70–74 50 1 (1.2) 1.35 (1.3)
GG All 36 1.6 (1.45) 1.9 (2.95)
55–59 8 1.95 (1.2) 1.95 (1.85)
60–64 12 1.7 (1.35) 2.25 (3.85)
65–69 11 1.6 (1.7) 2.4 (3.0)
70–74 5 1.2 (0.6) 1.4 (0.4)
rs3814113 TT All 393 1.2 (1.5) 1.6 (1.8)
55–59 97 1.3 (1.8) 1.7 (2.3)
60–64 125 1.2 (1.7) 1.6 (2.1)
65–69 109 1.2 (1.2) 1.5 (1.4)
70–74 62 1.1 (1.7) 1.45 (2.1)
TC All 379 1.3 (1.8) 1.8 (2.1)
55–59 94 1.4 (1.6) 1.7 (1.6)
60–64 125 1.4 (2.2) 2.1 (2.9)
65–69 92 1.4 (1.65) 1.6 (1.8)
70–74 68 1.1 (1.25) 1.7 (1.95)
CC All 76 1.2 (1.5) 1.8 (2.4)
55–59 11 2 (1.8) 2.1 (3.1)
60–64 26 1.2 (1) 1.85 (2.2)
65–69 29 1.3 (1.7) 2.1 (3.1)
70–74 10 0.9 (0.5) 1.05 (0.7)
Median ovarian volume and interquartile range at the first visit and median of the highest measured volume per woman is shown stratified by genotypes and age
groups.
doi:10.1371/journal.pone.0021731.t004
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risk factors summarized in Table 1 were associated with suspicious
TVU results. All subsequent analyses were restricted to Caucasians
only, leaving 43 women with baseline abnormal, 37 women with
incident abnormal, and 912 women with non-suspicious TVU
results.
Two SNPs, rs10756819 (OR=1.48, p=0.025) and rs12379183
(OR=1.46, p=0.046), showed a significant association with an
abnormal TVU result at any time during follow up, while two other
SNPs, rs3814113 and rs7861573, showed marginally significant
results. None of these associations was significant after adjusting for
multiple comparisons. After restricting to prevalent abnormal TVU
findings as outcome only, the effect increased substantially: All ten
SNPs on 9p22 showed increased ORs for suspicious TVU results at
the first screen (Table 2) and seven SNPs showed significant ORs:
rs12379183 (OR 2.10;p=0.002),rs10756819(OR2.00;p=0.002),
rs7861573 (OR 1.99; p=0.005), rs3814113 (OR 1.93; p=0.005),
rs10962656 (OR 1.73;p=0.042),rs10810666(OR1.72;p=0.031),
and rs4961501 (OR 1.68; p=0.04); the first four associations
remained significant afteradjustingformultiplecomparisons.When
restricting the TVU results to incident findings, none of the SNPs
were associated with suspicious screening results. Adjusting for age
did not change these results.
Figure 1 shows an LD map of the 10 SNPs analyzed in the
women from PLCO included in this analysis. Combinations of risk
alleles from the four most significant SNPs showed significant
associations with suspicious TVU results at the first screen (OR
1.95; p=0.003). Women with combinations of the two least
correlated significant SNPs (rs7861573 and rs10810666; r
2=0.29;
D9=0.63 in this population) had an OR of 1.61 (p=0.007) for
suspicious screening results (Table 3).
We explored the association of 9p22 SNPs with TVU
characteristics and CA-125 levels. For the rs12379183 SNP that
showed the strongest effect in this analysis, we observed a trend of
increasing ovarian volume measured at first ultrasound associated
with risk alleles in all age groups. For the rs3814113 SNP that was
most strongly associated with ovarian cancer risk [8], increasing
ovarian volume associated with risk alleles was only observed in the
55–59-year age group (Table 4). We analyzed the association of
9p22 genotypes with number, diameter, and volume of cysts among
women with abnormal TVU results (Table 5). Interestingly, women
carrying minor alleles had fewer cysts, with a mean number of 2.22
in women with two major alleles vs. 1.18 in women with at least one
minor allele of rs10756819 (p=0.01). In contrast, cyst volume was
non-significantly higher inwomen carrying at leastone minor allele.
We did not observe an association between 9p22 SNPs and further
TVU characteristics such as cyst volume and other cyst character-
istics. To analyze whether 9p22 SNPs were associated with CA-125
levels, we compared the medians of the first and the maximal CA-
125 values by genotype. None of the 10 SNPs studied showed an
association with CA-125 levels (data not shown).
Discussion
A large consortial GWAS effort recently identified several SNPs
on 9p22 that are associated with ovarian cancer risk [8]. The SNPs
are located in the region of the BNC2 gene which is involved in
ovarian development [9,10]. Spurred by these independent prior
findings on 9p22/BNC2 and ovarian biology we sought to leverage
available TVU and genetic data to study the association between
genetic variation and abnormal ovarian ultrasound findings. Our
study is an example of an exploration of biological mechanisms
following GWAS. Ovarian cancer screening using ultrasound and
CA-125 testing is currently evaluated in two large randomized
trials in the US and the UK. Previous analyses in PLCO have
shown that the positive predictive value of TVU-based screening is
low; almost all women with abnormal ultrasound findings do not
have and do not develop ovarian cancer [2]. Therefore, we do
consider these TVU findings as surrogates for biological changes
occurring in the ovary (with carcinogenic changes being one
option), rather than surrogates for cancer.
In our study of women without ovarian cancer, we observed a
significantly increased risk of abnormal suspicious TVU results for
several SNPs on 9p22 that have been found to be associated with
reduced ovarian cancer risk [8]. We did not expect that SNPs
associated with reduced ovarian cancer risk would correlate
positively with abnormalities on ultrasound. Although the findings
appear perplexing at first sight, it is conceivable that SNPs found
to lower the risk of ovarian cancer may be associated with
prevalent abnormal TVU findings.
We explored the association of 9p22 genotypes with morphologic
characteristics recorded during TVU in women with abnormal
TVU screening results. Although numbers were limited, we
observed that women carrying minor 9p22 alleles had ultrasound
features corresponding to complex ovarian cysts [16]. In a previous
analysis in PLCO, women with complex cysts were not found to
share established risk factors for ovarian malignancy [16]. In a more
recent analysis in PLCO, the risk of ovarian cancer among women
Table 5. 9p22 SNPs and ovarian cyst characteristics in TVU.
RS12379183 RS10756819 RS3814113
AA (n=16)
AB/BB
(n=25) p-value AA (n=10)
AB/BB
(n=32) p-value AA (n=11)
AB/BB
(n=30) p-value
Number of
cysts
Mean 1.69 1.23 0.21 2.22 1.18 0.01 1.82 1.19 0.08
SE 0.38 0.15 0.64 0.12 0.46 0.13
Cyst diameter
(cm)
Mean 3.87 3.74 0.81 3.56 3.86 0.48 3.83 3.76 0.92
SE 0.24 0.46 0.36 0.36 0.39 0.38
Cyst volume
(cm
3)
Mean 35.38 60.78 0.21 29.36 56.92 0.07 38.03 55.5 0.34
SE 5.3 18.85 7.46 14.79 9.14 15.72
A=major allele; B=minor allele. SE=standard error. T-test p-values are shown.
doi:10.1371/journal.pone.0021731.t005
9p22 SNPs and Abnormal Ovarian Ultrasound Results
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21731with prevalent cysts was slightly, but non-significantly lower
compared to women with no cysts [17]. Unfortunately, histology
reports of benign outcomes in women treated for abnormal TVU
results were not systematically collected in PLCO and could not be
evaluated in relation to 9p22 genotypes.
Most importantly, our findings require independent confirma-
tion, which is challenging, as there are only few resources that
provide both TVU screening information and genetic data from a
population-based study. If confirmed, our data suggest that some
genes potentially protective against ovarian cancer actually are
associated with suspicious TVU findings such as increased ovarian
volume or complex cysts that gradually arise over decades and are
detected at the first TVU screen.
The biology of ovarian cancer development is not well
understood. It has been suggested that incessant ovulation,
associated with repeated disruption and micro-traumas of the
ovarian surface epithelium, may lead to initial transformation [18].
Other theories suggest that hormonal stimulation of the epithe-
lium, especially by estrogens and estrogen metabolites, may initiate
carcinogenesis [19]. There is now growing evidence that at least a
subset of ovarian cancers may arise in the Fallopian tube and
implant in the ovaries early on [20].
Ovarian abnormalities associated with SNPs at the 9p22 locus
may protect against cancer development by interfering with these
carcinogenic mechanisms, e.g. by reducing the number of lifetime
ovulations or by modulating the exposure of ovarian tissue to
endogenous or exogenous hormones. Ovarian cysts may impede
implantation of early transformed cell clones derived from the
Fallopian tube. Furthermore, although we did not see any
evidence in PLCO, we cannot exclude that the reduced ovarian
cancer risk associated with these SNPs is related to more frequent
oophorectomies following suspicious TVU results, rather than to a
direct biological mechanism.
If the 9p22 locus is associated with false positive ovarian cancer
screening results, genotyping might have influence on the
interpretation of TVU results.
A recent study demonstrated that cancer-related SNPs may
influence prostate cancer risk estimates related to prostate specific
antigen levels [21]. In a study of breast cancer risk models, 10
common genetic variants associated with breast cancer risk had
similar performance as the Gail model based on clinical at
predicting breast cancer risk, but adding the SNPs to the clinical
data only modestly improved risk prediction [22]. Replication of
our findings in other studies, evaluation of risk factors associated
with the 9p22 locus and extension to ovarian cancer cases are
necessary to understand the complex relationship between
screening abnormalities and ovarian carcinogenesis and to
evaluate whether this locus can influence the risk stratification of
TVU screening. Moreover, detailed mapping of the region is
needed to identify the actual ‘at risk’ and protective haplotypes.
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